GREY:ICOTF - Post by User
Post by
Yassinon Oct 02, 2018 10:39am
79 Views
Post# 28728614
iCo may receive up to $32M in milestone payments
iCo may receive up to $32M in milestone payments - iCo's licensee recently received Fast Track designation for iCo-008 use in bullous pemphigoid (BP) by the US Food and Drug Administration (FDA). The FDA has also recently granted orphan drug designation to iCo-008 for the treatment of bullous pemphigoid. Under this license agreement, iCo may receive up to $32M in milestone payments, beginning with a material payment upon first dose in a pivotal BP trial. iCo's licensee continues to make significant development progress and is currently planning for a pivotal clinical study for BP and expects preliminary data from its second Phase 2 study in ulcerative colitis (UC) in Q1 2019.